Adult Attention Deficit Hyperactivity Disorder emerging Market… and Big Pharma Strategies

Big Pharma’s newest invention: adult ADHD

Big Pharma’s newest invention: Adult ADHD
Who belongs to this untapped market? You do, of course

There is good news and bad news about attention deficit/hyperactivity disorder (ADHD) — that is, if you’re a drug company. The bad news is the kid market has peaked out with 4.5 million U.S. children now carrying the label. The good news is adult ADHD is an emerging market. In fact, adult ADHD, with symptoms similar to pediatric ADHD such as impulsivity, distractibility and difficulty paying attention, following instructions and meeting deadlines, is the next big thing “.

Read Big Pharma’s newest invention: Adult ADHD
by Martha Rosenberg, Oct 1, 2012

8 thoughts on “Adult Attention Deficit Hyperactivity Disorder emerging Market… and Big Pharma Strategies”

Have your say ! Share your views